“We can cut preclinical development from five years to 18 months. Molecules which are AI-enabled in some way seem to be doing better in Phase 1 than standard molecules.” – Dr. Eva-Maria Hempe, Head of Healthcare & Life Sciences EMEA
Aizon is on a mission to integrate modern computing into the complex arena of GMP manufacturing processes in life sciences. In the latest episode of the PharmaSource podcast we sat down with Claus Abildgren, Chief Revenue Officer at Aizon, and
Pharma companies have high confidence in the value of generative artificial intelligence (AI). According to a recent Bain survey:
Stay ahead of trends and best practices 
Exclusive downloads and podcasts 
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
